FGFR

Fibroblast growth factor receptor

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins. Some of these receptors are involved in pathological conditions. A point mutation in FGFR3 can lead to achondroplasia. Five distinct membrane FGFR have been identified in vertebrates and all of them belong to the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). The fibroblast growth factor family constitutes one of the most important groups of paracrine factors that act during development. They are responsible for determining certain cells to become mesoderm, for the production of blood vessels, for limb outgrowth, and for the growth and differentiation of numerous cell types.

FGFR Inhibitors

(Z)-Orantinib

((Z)-SU6668; (Z)-TSU-68)

Cat. No.: HY-10517A

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of **Flk1/KDR**, **PDGFRβ**, and **FGFR1**, with IC_{50}s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

2,5-Dihydroxybenzoic acid

Cat. No.: HY-W001179

2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of **fibroblast growth factors**.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

2,5-Dihydroxybenzoic acid-d3

Cat. No.: HY-W001179S

2,5-Dihydroxybenzoic acid-d3 is the deuterium labeled 2,5-Dihydroxybenzoic acid.
2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of **fibroblast growth factors**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 50 mg

3-Methylthienyl-carbonyl-JNJ-7706621

Cat. No.: HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of **cyclin-dependent kinase (CDK)**, with IC_{50}s of 6.4 nM and 2 nM for **CDK1/cyclinB** and **CDK2/cyclinA**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alofanib

(RPT835)

Cat. No.: HY-17601

Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (**FGFR2**). Anticancer and antiangiogenic activity.



Purity: 98.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Aprutumab

(BAY 1179470)

Cat. No.: HY-P99007

Aprutumab (BAY 1179470) is a fully human **FGFR2** monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research.

Aprutumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARQ 069

Cat. No.: HY-101544

ARQ 069, an analog of ARQ 523, inhibits **FGFR** in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC_{50}s of 0.84 μM and 1.23 μM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ASP5878

Cat. No.: HY-19983

ASP5878 is an oral active inhibitor of **FGFR 1, 2, 3, and 4**, with IC_{50} values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity.



Purity: 99.86%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD4547

Cat. No.: HY-13330

AZD4547 is a potent inhibitor of the **FGFR** family with IC_{50}s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Bemarituzumab

Cat. No.: HY-P99010

Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against **FGFR2b** (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.

Bemarituzumab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

BLU9931

Cat. No.: HY-12823

BLU9931 is a potent, highly selective, and irreversible **fibroblast growth factor receptor 4 (FGFR4)** inhibitor with an IC_{50} of 3 nM and a K_d of 6 nM. BLU9931 has significant antitumor activity.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BO-264

Cat. No.: HY-135960

BO-264 is a highly potent and orally active **transforming acidic coiled-coil 3 (TACC3)** inhibitor with an IC_{50} of 188 nM and a K_d of 1.5 nM. BO-264 specifically blocks the function of **FGFR3-TACC3** fusion protein.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg, 250 mg

CP-547632

Cat. No.: HY-13302

CP-547632 is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy.



Purity: 98.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632 hydrochloride

Cat. No.: HY-13302B

CP-547632 hydrochloride is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs).



Purity: 98.24%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-547632 TFA

Cat. No.: HY-13302C

CP-547632 TFA is an orally active, ATP-competitive and potent **VEGFR-2** and **FGF** kinases inhibitor with IC_{50}s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CPL304110

Cat. No.: HY-131908

CPL304110 is a potent, orally active and selective inhibitor of **fibroblast growth factor receptors FGFR (1-3)**, with IC_{50} values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Derazantinib

(ARQ-087)

Cat. No.: HY-19981

Derazantinib (ARQ-087) is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against **FGFR1-3** chondrocytes with IC_{50}s of 4.5, 1.8, and 4.5 nM, respectively.



Purity: 99.18%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Derazantinib Racemate

(ARQ-087 Racemate)

Cat. No.: HY-19981A

Derazantinib Racemate (ARQ-087 Racemate) is the racemate of Derazantinib. Derazantinib is an orally bioavailable, ATP competitive tyrosine kinase inhibitor; exhibits potent activity against **FGFR1-3** chondrocytes with IC_{50}s of 4.5, 1.8, and 4.5 nM, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg

Dovitinib

(CHIR-258; TKI258)

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate)

Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.62%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate)

Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E7090

Cat. No.: HY-101466

E7090 is an orally available, potent, and selective **FGFR** inhibitor with IC_{50}s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for **FGFR1/FGFR2/FGFR3/FGFR4**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

E7090 succinate

Cat. No.: HY-101466A

E7090 succinate is an orally available, selective and potent inhibitor of **FGFR1, FGFR2** and **FGFR3** tyrosine kinase activities, with IC_{50} values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

EOC317

(ACTB-1003)

Cat. No.: HY-16025

EOC317 (ACTB-1003) is an oral kinase inhibitor with IC_{50}s of 6, 2 and 4 nM for **FGFR1**, **VEGFR2** and **Tie-2**.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Erdafitinib

(JNJ-42756493)

Cat. No.: HY-18708

Erdafitinib (JNJ-42756493) is a potent and orally available **FGFR** family inhibitor; inhibits FGFR1/2/3/4 with IC_{50}s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.



Purity: 99.66%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ferulic acid

(Coniferic acid)

Cat. No.: HY-N0060

Ferulic acid is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Ferulic acid sodium

(Coniferic acid sodium)

Cat. No.: HY-N0060A

Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: ≥99.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Ferulic acid-13C3

Cat. No.: HY-N0060S1

Ferulic acid-13C3 is the 13C-labeled Ferulic acid. Ferulic acid is a novel fibroblast growth factor receptor 1 (**FGFR1**) inhibitor with IC_{50}s of 3.78 and 12.5 μM for **FGFR1** and **FGFR2**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR-IN-1

Cat. No.: HY-145043

FGFR-IN-1 is a potent **FGFR** inhibitor with an IC_{50} of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219).



Purity: 99.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGFR-IN-2

Cat. No.: HY-142921

FGFR-IN-2 (compound 1) is a potent **FGFR** inhibitor with IC_{50}s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR1 inhibitor-2

Cat. No.: HY-139376

FGFR1 inhibitor-2 is a **FGFR1** inhibitor (IC_{50} is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR1/DDR2 inhibitor 1

Cat. No.: HY-114311

FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of **fibroblast growth factor receptor 1 (FGFR1)** and **discoindin domain receptor 2 (DDR2)**, with IC_{50} values of 31.1 nM and 3.2 nM, respectively. Antitumor activity.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGFR2-IN-2

Cat. No.: HY-145231

FGFR2-IN-2 (Compound 38) is a selective **FGFR2** inhibitor with IC_{50}s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-1

Cat. No.: HY-100631

FGFR4-IN-1 is a potent inhibiotr of **FGFR4** with IC_{50} of 0.7 nM.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FGFR4-IN-10

Cat. No.: HY-146541

FGFR4-IN-10 (compound 5a) is a potent and selective **FGFR4** inhibitor with an IC_{50} value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-4

Cat. No.: HY-129181

FGFR4-IN-4 (compound 693) is a **FGFR4** inhibitor with anti-tumor activity, extracted from patent WO2018113584A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-5

Cat. No.: HY-131704

FGFR4-IN-5 is a potent and selective covalent **FGFR4** inhibitor with an IC_{50} of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FGFR4-IN-6

Cat. No.: HY-143881

FGFR4-IN-6 (Compound 9ka) is a covalently reversible **FGFR4** inhibitor with an IC_{50} value of 5.4 nM. FGFR4-IN-6 also exhibits good oral pharmacokinetic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-7

Cat. No.: HY-115902

FGFR4-IN-7 (Compound C3) is a covalent reversible **FGFR4** inhibitor with an IC_{50} value of 0.42 μM. FGFR4-IN-7 induces **apoptosis** via the FGFR4 signaling pathway blockage. FGFR4-IN-7 can be used for the research of hepatocellular carcinoma (HCC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FGFR4-IN-8

Cat. No.: HY-145836

FGFR4-IN-8 (Compound 7v) is an ATP-competitive, highly selective covalent inhibitor of wild-type and gatekeeper mutant **FGFR4**. FGFR4-IN-8 exhibits excellent potency against FGFR4, $FGFR4^{V550L}$, $FGFR4^{V550M}$ and $FGFR4^{C552S}$ with IC_{50}s of 0.5, 0.25, 1.6, 931 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FIIN-1

(FGFR irreversible inhibitor-1)

Cat. No.: HY-15813

FIIN-1 is a potent, irreversible, selective **FGFR** inhibitor. FIIN-1 binds to **FGFR1/2/3/4** and **Flt1/4** with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC_{50}s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FIIN-2

Cat. No.: HY-18602

FIIN-2 is an irreversible inhibitor of **FGFR** with an IC_{50} of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

FIIN-3

Cat. No.: HY-18603

FIIN-3 is an irreversible inhibitor of **FGFR** with an IC_{50} of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Fisogatinib

(BLU-554)

Cat. No.: HY-100492

Fisogatinib (BLU-554) is a potent, highly selective and orally active **fibroblast growth factor receptor 4 (FGFR4)** inhibitor with an IC_{50} of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on **FGFR4** signalling.



Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Formononetin

(Biochanin B; Flavosil; Formononetol)

Cat. No.: HY-N0183

Formononetin is a potent **FGFR2** inhibitor with an IC_{50} of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Futibatinib

(TAS-120)

Cat. No.: HY-100818

Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible **FGFR** inhibitor, with IC_{50}s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively.



Purity: 99.46%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gandotinib

(LY2784544)

Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Gunagratinib

(ICP-192)

Cat. No.: HY-132817

Gunagratinib (ICP-192) is a low toxicity and orally active **pan-FGFR** (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits **FGFR** activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Heparan Sulfate

Cat. No.: HY-101916

Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Infigratinib

(BGJ-398; NVP-BGJ398)

Cat. No.: HY-13311

Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the **FGFR** family with IC_{50}s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Infigratinib phosphate

(BGJ-398 phosphate; NVP-BGJ398 phosphate)

Cat. No.: HY-13311A

Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the **FGFR** family with IC_{50} of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for **FGFR1**, **FGFR2**, **FGFR3**, and **FGFR4**, respectively.



Purity: 97.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

JK-P3

Cat. No.: HY-108933

JK-P3 is a potent and pan **VEGFR2** inhibitor, with IC_{50}s of 7.83 μM, 27 μM and 5.18 μM for VEGFR2, FGFR1 and FGFR3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KHS101 hydrochloride

Cat. No.: HY-10996A

KHS101 hydrochloride could selectively induce a neuronal differentiation phenotype and interacts with transforming acidic coiled-coil-containing protein 3 **(TACC3)**.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL^{T315I}** and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib

(E7080)

Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate)

Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib-d4

(E7080-d4)

Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lenvatinib-d5

(E7080-d5) Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lucitanib

(E-3810) Cat. No.: HY-15391

Lucitanib (E-3810) is a novel dual inhibitor of **VEGFR** and **FGFR**, potently and selectively inhibits **VEGFR1**, **VEGFR2**, **VEGFR3**, **FGFR1** and **FGFR2** with IC_{50}s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively.



Purity: 98.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2874455

Cat. No.: HY-13304

LY2874455 is a **pan-FGFR** inhibitor with IC_{50}s of 2.8, 2.6, 6.4, 6 nM for **FGFR1**, **FGFR2**, **FGFR3**, **FGFR4**, respectively.



Purity: 98.06%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Masitinib

(AB1010) Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate) Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

MAX-40279

Cat. No.: HY-145723

MAX-40279 is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hemiadipate

Cat. No.: HY-145723C

MAX-40279 hemiadipate is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hemifumarate

Cat. No.: HY-145723B

MAX-40279 hemifumarate is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hemifumarate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MAX-40279 hydrochloride

Cat. No.: HY-145723A

MAX-40279 hydrochloride is a dual and potent inhibitor of **FLT3** kinase and **FGFR** kinase. MAX-40279 hydrochloride has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nintedanib

(BIBF 1120) Cat. No.: HY-50904

Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Nintedanib esylate

(BIBF 1120 esylate) Cat. No.: HY-11106

Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Nintedanib-13C,d3

(BIBF 1120-13C,d3) Cat. No.: HY-50904S1

Nintedanib-13C,d3 is the 13C- and deuterium labeled. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nintedanib-d3

(BIBF 1120-d3) Cat. No.: HY-50904S

Nintedanib-d3 (BIBF 1120-d3) is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for **VEGFR1/2/3**, **FGFR1/2/3** and **PDGFRα/β** with IC_{50}s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Nintedanib-d8

(BIBF 1120-d8) Cat. No.: HY-50904S2

Nintedanib-d8 is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ODM-203

Cat. No.: HY-119367

ODM-203 is a potent **FGFR** and **VEGFR** families inhibitor with IC_{50}s of 11, 16, 6, 35 nM towards recombinant FGFR1, FGFR2, FGFR3 and FGFR4 as well as 26, 9, 5 nM towards VEGFR1, VEGFR2 and VEGFR3, respectively. ODM-203 exhibits strong anti-tumor activity and induces anti-tumor immunity.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Orantinib

(SU6668; TSU-68) Cat. No.: HY-10517

Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with K_is of 2.1 μM, 8 nM and 1.2 μM for **Flt-1**, **PDGFRβ** and **FGFR1**, respectively.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pazopanib

(GW786034) Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib-d6

(GW786034-d6) Cat. No.: HY-10208S

Pazopanib-d6 (GW786034-d6) is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-166866

Cat. No.: HY-101296

PD166866 is a selective **FGFR1** tyrosine kinase inhibitor with an IC_{50} of 52.4 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PD173074

Cat. No.: HY-10321

PD173074 is a potent **FGFR1** inhibitor with an IC_{50} of 25 nM and also inhibits **VEGFR2** with an IC_{50} of 100-200 nM, showing 1000-fold selectivity for FGFR1 over PDGFR and c-Src.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pemigatinib

(INCB054828)

Cat. No.: HY-109099

Pemigatinib (INCB054828) is an orally active, selective **FGFR** inhibitor with IC_{50}s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Picrasidine Q

Cat. No.: HY-N9507

Picrasidine Q, an alkaloid component extracted from Angelica keiskei species, has the capacity of anti-cell transformation and anti-cancer. Picrasidine Q induces cell **apoptosis** and G1 phase arrest in human esophageal cancer cell lines, and directly inhibits **FGFR2** kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Ponatinib

(AP24534)

Cat. No.: HY-12047

Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 99.43%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Ponatinib hydrochloride

(AP24534 hydrochloride)

Cat. No.: HY-108766

Ponatinib (AP24534) hydrochloride is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ponatinib-d8

(AP24534-d8)

Cat. No.: HY-12047S

Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC_{50}s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PP58

Cat. No.: HY-18622

PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar IC_{50} values.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

PRN1371

Cat. No.: HY-101768

PRN1371 is a highly selective and potent **FGFR1-4** and **CSF1R** inhibitor with IC_{50}s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively.



Purity: 99.72%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

R1530

Cat. No.: HY-13737

R1530 is a highly potent, orally active, dual-acting **mitosis/angiogenesis** inhibitor, with anti-tumor and anti-angiogenic activities. R1530 is a multikinase inhibitor which binds to 31 kinases with K_ds of <500 nM.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Roblitinib

(FGF-401)

Cat. No.: HY-101568

Roblitinib (FGF-401) is an orally active and highly selective **FGFR4** inhibitor with an IC_{50} of 1.9 nM. Roblitinib has antitumor activity.



Purity: 99.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Rogaratinib

(BAY1163877)

Cat. No.: HY-100019

Rogaratinib (BAY1163877) is a potent and selective **fibroblast growth factor receptor** (**FGFR**) inhibitor.



Purity: 99.86%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

S49076

Cat. No.: HY-12965

S49076 is a novel, potent inhibitor of **MET**, **AXL/MER**, and **FGFR1/2/3** with IC_{50} values below 20 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SM1-71

Cat. No.: HY-136848

SM1-71 (compound 5) is a potent **TAK1** inhibitor, with a K_i of 160 nM, it also can covalently inhibit **MKNK2**, **MAP2K1/2/3/4/6/7**, **GAK**, **AAK1**, **BMP2K**, **MAP3K7**, **MAPKAPK5**, **GSK3A/B**, **MAPK1/3**, **SRC**, **YES1**, **FGFR1**, **ZAK (MLTK)**, **MAP3K1**, **LIMK1** and **RSK2**.



Purity: 96.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SNIPER(TACC3)-11

Cat. No.: HY-145895

SNIPER(TACC3)-11 is a potent **FGFR3-TACC3** degrader. SNIPER(TACC3)-11 reduces FGFR3-TACC3 protein levels and suppressed the growth of FGFR3-TACC3 positive cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SSR128129E

(SSR)

Cat. No.: HY-15599

SSR128129E is an orally available and allosteric **FGFR** inhibitor with an IC_{50} of 1.9 μM for FGFR1.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

SSR128129E free acid

(SSR free acid)

Cat. No.: HY-15599A

SSR128129E free acid is an orally available and allosteric **FGFR** inhibitor with an IC_{50} of 1.9 μM for FGFR1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU 5402

Cat. No.: HY-10407

SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC_{50} of 20 nM, 30 nM, and 510 nM for **VEGFR2**, **FGFR1**, and **PDGFRβ**, respectively.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU11652

Cat. No.: HY-112452

SU11652 is a potent **receptor tyrosine kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including **VEGFR**, **FGFR**, **PDGFR**, and **Kit**. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU4984

Cat. No.: HY-118203

SU4984 is a protein tyrosine kinase inhibitor, with an IC_{50} of 10-20 μM for **fibroblast growth factor receptor 1 (FGFR1)**. SU4984 is also inhibits **platelet-derived growth factor receptor**, and **insulin receptor**. SU4984 can be used for the research of cancer.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sulfatinib

(HMPL-012)

Cat. No.: HY-12297

Sulfatinib (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against **VEGFR1/2/3**, **FGFR1** and **CSF1R** with IC_{50}s of in a range of 1 to 24 nM.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SUN11602

Cat. No.: HY-101493

SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Surfen dihydrochloride

(Aminoquincarbamide dihydrochloride)

Cat. No.: HY-122704A

Surfen dihydrochloride is a potent **HS (heparan sulfate)** antagonist. Surfen binds to glycosaminoglycans. Surfen neutralizes the anticoagulant activity of both unfractionated and low molecular weight heparins.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572

Cat. No.: HY-10184

TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG 100572 Hydrochloride

Cat. No.: HY-10185

TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has IC_{50}s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg

TG 100801

Cat. No.: HY-10186

TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg

TG 100801 Hydrochloride

Cat. No.: HY-10187

TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Tyrosine kinase-IN-1

Cat. No.: HY-100315

Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 4, 20, 4, 2 nM for **KDR**, **Flt-1**, **FGFR1** and **PDGFRα**, respectively.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zoligratinib

(Debio 1347; CH5183284) **Cat. No.:** HY-19957

Zoligratinib (Debio 1347) is an orally available and selective **FGFR** inhibitor with **IC_{50}**s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg